DXCM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.24B

+11.43%

0.647

+43.78%

1.18B

+13.72%

0.474

+48.2%

1.29B

+11.73%

0.598

+24.5%

Estimates Revision

The market is revising Upward the revenue expectations for DexCom, Inc. (DXCM) for FY2025, with the revenue forecasts being adjusted by 0.47% over the past three months. During the same period, the stock price has changed by -1.00%.

Revenue Estimates for FY2025

Revise Upward

+0.47%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.74%

In Past 3 Month

Stock Price

Go Down

-1.00%

In Past 3 Month

22 Analyst Rating

Wall Street analysts forecast DXCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DXCM is 85.75 USD with a low forecast of 63.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

5 Hold

0 Sell

Strong Buy

Current: 0.000

Low

63.00

Averages

85.75

High

112.00

Current: 0.000

Low

63.00

Averages

85.75

High

112.00

Bernstein

Outperform

maintain

$84 -> $86

2026-01-09

New

Reason

Bernstein

Price Target

$84 -> $86

2026-01-09

New

maintain

Outperform

Reason

Bernstein raised the firm's price target on DexCom to $86 from $84 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.

Raymond James

Strong Buy

maintain

$260

2025-12-18

Reason

Raymond James

Price Target

$260

2025-12-18

maintain

Strong Buy

Reason

Jabil's (JBL) recent stock weakness does not reflect any negative surprises, as earnings, guidance, and management commentary were in line, and claims that Jabil is losing share at Dexcom (DXCM) are incorrect and is "categorically not happening," Raymond James tells investors in a research note. Near-term headwinds include elevated interest expense, a higher FY27 tax rate, and a temporary AI-related capacity retrofit, but these are well understood by investors and expected to ease as the new North Carolina facility ramps quickly toward full production, the firm adds. Raymond James has a Strong Buy rating and $260 price target on Jabil shares.

Mizuho

Outperform

maintain

$75 -> $78

2025-12-17

Reason

Mizuho

Price Target

$75 -> $78

2025-12-17

maintain

Outperform

Reason

Mizuho raised the firm's price target on DexCom to $78 from $75 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices and diagnostics group as part of its 2026 outlook. Despite stock valuations trending back toward two-year highs post the Q3 reports, there is potential for further multiple expansion "under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector," the analyst tells investors in a research note.

Citi

Buy

maintain

$75 -> $77

2025-12-11

Reason

Citi

Price Target

$75 -> $77

2025-12-11

maintain

Buy

Reason

Citi raised the firm's price target on DexCom to $77 from $75 and keeps a Buy rating on the shares. Citi also opened an "upside 90-day catalyst watch" on DexCom. The firm sees the stock moving higher on the company's 2026 guidance in January.

Morgan Stanley

Patrick Wood

Equal Weight

Overweight

upgrade

$75

2025-12-02

Reason

Morgan Stanley

Patrick Wood

Price Target

$75

2025-12-02

upgrade

Equal Weight

Overweight

Reason

Morgan Stanley analyst Patrick Wood upgraded DexCom to Overweight from Equal Weight with a $75 price target.

Morgan Stanley

Equal Weight -> Overweight

upgrade

$63 -> $75

2025-12-02

Reason

Morgan Stanley

Price Target

$63 -> $75

2025-12-02

upgrade

Equal Weight -> Overweight

Reason

As previously reported, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, up from $63, citing signs that the company is already turning the corner from a number of operational challenges while valuation remains at trough levels. The firm expects this turn to become apparent in the full results due in January or February, adding that it believes the G7 15-day rollout's impact on margins in the year ahead is "underappreciated" and it expects the stock to re-rate as catalysts play out.

Valuation Metrics

The current forward P/E ratio for Dexcom Inc (DXCM.O) is 27.81, compared to its 5-year average forward P/E of 89.08. For a more detailed relative valuation and DCF analysis to assess Dexcom Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

89.08

Current PE

27.81

Overvalued PE

137.23

Undervalued PE

40.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

46.16

Current EV/EBITDA

15.86

Overvalued EV/EBITDA

71.75

Undervalued EV/EBITDA

20.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

11.29

Current PS

5.13

Overvalued PS

15.42

Undervalued PS

7.16

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 161.76% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 161.76% over the last month.

Sold

Bought

DXCM News & Events

Events Timeline

No data

News

7.0

2025-12-31Barron's

Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.

7.0

2025-12-30Fool

Vertex Pharmaceuticals and DexCom Project Growth Potential for 2026

7.0

2025-12-30NASDAQ.COM

Vertex Pharmaceuticals Poised for New Product Launches in 2026

People Also Watch

Frequently Asked Questions

What is Dexcom Inc (DXCM) stock price today?

The current price of DXCM is 67.4 USD — it has decreased -1.51 % in the last trading day.

What is Dexcom Inc (DXCM)'s business?

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

What is the price predicton of DXCM Stock?

What is Dexcom Inc (DXCM)'s revenue for the last quarter?

Dexcom Inc revenue for the last quarter amounts to 1.21B USD, increased 21.64 % YoY.

What is Dexcom Inc (DXCM)'s earnings per share (EPS) for the last quarter?

Dexcom Inc. EPS for the last quarter amounts to 0.70 USD, increased 112.12 % YoY.

What changes have occurred in the market's expectations for Dexcom Inc (DXCM)'s fundamentals?

How many employees does Dexcom Inc (DXCM). have?

Dexcom Inc (DXCM) has 10300 emplpoyees as of January 10 2026.

What is Dexcom Inc (DXCM) market cap?

Today DXCM has the market capitalization of 26.29B USD.